Claims for Patent: 11,254,963

✉ Email this page to a colleague

Summary for Patent: 11,254,963

Title:	Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins
Abstract:	The present invention relates to a method for manipulating the high mannose glycoform content of recombinant glycoproteins by regulating ornithine metabolism during cell culture.
Inventor(s):	Sohye Kang, Chung HUANG, Jr., Hedieh BARKHORDARIAN, Pavel Bondarenko, Zhongqi ZHANG
Assignee:	Amgen Inc
Application Number:	US16/676,340

Details for Patent 11,254,963

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	June 01, 2010	11,254,963	2039-11-06
Amgen Inc.	XGEVA	denosumab	Injection	125320	November 18, 2010	11,254,963	2039-11-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 11,254,963

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015105609	⤷ Get Started Free
United States of America	2020071738	⤷ Get Started Free
United States of America	2016333385	⤷ Get Started Free
United States of America	10513723	⤷ Get Started Free
Singapore	11201605640U	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.